newsfilter
← Earnings
Earnings Releases·

MapLight Therapeutics — Third Quarter 2026 Earnings Summary

  • Cash and investments increased to $463.4 million as of September 30, 2026, from $453.1 million at year-end 2025, while total operating expenses rose to $55.3 million from $31.5 million in the prior year period, resulting in a net loss of $51.6 million compared to $29.4 million previously.
  • The company completed a $150 million private placement in August 2026 to fund the advancement of ML-007C-MA and general corporate purposes, with current cash expected to sustain operations through 2028.
  • Clinical timelines were adjusted to expect ZEPHYR-2 Phase 3 schizophrenia results in H2 2027 and VISTA Phase 2 Alzheimer's disease psychosis results in 2028, following positive Phase 2 data for both indications.
  • Management plans to engage the FDA for End-of-Phase 2 meetings regarding ML-007C-MA and ML-004, with future development options for ML-004 including potential strategic collaborations, while pausing investment in preclinical programs beyond near-term milestones.
Company
MAPLIGHT THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology